Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation - PubMed (original) (raw)
Comparative Study
Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation
E Vance et al. Bone Marrow Transplant. 1998 Oct.
Abstract
Antibody concentrations to vaccine-preventable diseases decline following BMT and an optimal schedule for vaccination after transplant has not been established. We examined antibody responses to tetanus toxoid (TT) and Haemophilus influenzae type b-conjugate (HIB) vaccines of BMT patients immunized at 6, 12 and 24 months (6 month group, n = 21) and compared them to those previously reported for patients immunized at 3, 6, 12 and 24 months (3 month group, n = 74) or at 12 and 24 months (12 month group, n = 17) following transplantation. Geometric mean total anti-HIB and IgG anti-TT concentrations were significantly higher after the 12 month dose in the 3 and 6 month immunization groups compared to the group who received their first dose at 12 months. Although HIB antibody concentrations were higher in the 3 month and 6 month groups 12 to 24 months after BMT, the proportion of patients with protective levels was not significantly different from the proportion protected in the 12 month group. Following the 24 month immunizations, geometric mean antibody concentrations to HIB and TT were similar for all three immunization groups. The proportion of patients in each group with protective levels of HIB antibody after the 24 month dose was > or = 80%. A two dose schedule of HIB and TT vaccines at 12 and 24 months after BMT should afford protection.
Similar articles
- Antibody responses to tetanus toxoid and Haemophilus influenzae type b conjugate vaccines following autologous peripheral blood stem cell transplantation (PBSCT).
Chan CY, Molrine DC, Antin JH, Wheeler C, Guinan EC, Weinstein HJ, Phillips NR, McGarigle C, Harvey S, Schnipper C, Ambrosino DM. Chan CY, et al. Bone Marrow Transplant. 1997 Jul;20(1):33-8. doi: 10.1038/sj.bmt.1700843. Bone Marrow Transplant. 1997. PMID: 9232253 Clinical Trial. - Haemophilus influenzae type b (HIB)-conjugate immunization before bone marrow harvest in autologous bone marrow transplantation.
Molrine DC, Guinan EC, Antin JH, Wheeler C, Parsons SK, Weinstein HJ, McGarigle C, Blanding P, Phillips NR, Ciamarra A, George S, Ambrosino DM. Molrine DC, et al. Bone Marrow Transplant. 1996 Jun;17(6):1149-55. Bone Marrow Transplant. 1996. PMID: 8807128 - Dose response of CRM197 and tetanus toxoid-conjugated Haemophilus influenzae type b vaccines.
Huebner RE, Nicol M, Mothupi R, Käyhty H, Mbelle N, Khomo E, Klugman KP. Huebner RE, et al. Vaccine. 2004 Dec 21;23(6):802-6. doi: 10.1016/j.vaccine.2004.06.052. Vaccine. 2004. PMID: 15542205 Clinical Trial. - Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, Dieussaert I, Schuerman L. Knuf M, et al. Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S97-S108. doi: 10.1097/INF.0b013e318199f61b. Pediatr Infect Dis J. 2009. PMID: 19325452 Review.
Cited by
- Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.
Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Krüger W, Mousset S, Neuburger S, Neumann S, Penack O, Silling G, Vehreschild JJ, Einsele H, Maschmeyer G; Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology (AGIHO/DGHO) and the DAG-KBT (German Working Group for Blood and Marrow Transplantation). Ullmann AJ, et al. Ann Hematol. 2016 Sep;95(9):1435-55. doi: 10.1007/s00277-016-2711-1. Epub 2016 Jun 24. Ann Hematol. 2016. PMID: 27339055 Free PMC article. - Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (III) Impfen bei hämatologischen und onkologischen Erkrankungen (antineoplastische Therapie, Stammzelltransplantation), Organtransplantation und Asplenie.
Laws HJ, Baumann U, Bogdan C, Burchard G, Christopeit M, Hecht J, Heininger U, Hilgendorf I, Kern W, Kling K, Kobbe G, Külper W, Lehrnbecher T, Meisel R, Simon A, Ullmann A, de Wit M, Zepp F. Laws HJ, et al. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020 May;63(5):588-644. doi: 10.1007/s00103-020-03123-w. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020. PMID: 32350583 Free PMC article. German. No abstract available. - Immune responses to inhalant allergens.
Thomas WR, Hales BJ. Thomas WR, et al. World Allergy Organ J. 2008 Jun;1(6):89-95. doi: 10.1097/WOX.0b013e3181788324. World Allergy Organ J. 2008. PMID: 23282404 Free PMC article. - Species-specific and cross-reactive IgG1 antibody binding to viral capsid protein 1 (VP1) antigens of human rhinovirus species A, B and C.
Iwasaki J, Smith WA, Stone SR, Thomas WR, Hales BJ. Iwasaki J, et al. PLoS One. 2013 Aug 7;8(8):e70552. doi: 10.1371/journal.pone.0070552. eCollection 2013. PLoS One. 2013. PMID: 23950960 Free PMC article. - Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.
Ambati A, Boas LS, Ljungman P, Testa L, de Oliveira JF, Aoun M, Colturato V, Maeurer M, Machado CM. Ambati A, et al. Bone Marrow Transplant. 2015 Jun;50(6):858-64. doi: 10.1038/bmt.2015.47. Epub 2015 Mar 23. Bone Marrow Transplant. 2015. PMID: 25798680 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical